Prinon compounds and their use in the treatment of cancer

摘要

This specification generally relates to the compounds of formula (I) and the pharmaceutically acceptable salt thereof (formula 1, R1, A1, A2 and A3 having one or more meanings defined herein).This specification also relates to the use of such compounds and their salts to treat or prevent DNA to PK mediated diseases including cancer.The pharmaceutical composition comprising these compounds and salts; Kit containing such compounds and salts; Methods for producing such compounds and salts; Intermediates useful in the manufacture of such compounds and salts; The present invention relates to a method of treating DNA PK mediated diseases including cancer using such compounds and salts.